.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
This 24-week, double-blind, randomized trial evaluated adjunctive sulforaphane versus placebo in patients with chronic schizophrenia and significant negative symptoms, while existing antipsychotic regimens remained unchanged. A total of 42 patients were included in the statistical analysis: 28 received sulforaphane and 14 received placebo. Sulforaphane significantly reduced the negative-symptom score derived from the five-factor Positive and Negative Syndrome Scale (PANSS) model compared with placebo (p=0.007), with a significant time-by-treatment-group interaction (p=0.023). The between-group difference in negative symptoms was more pronounced at 12 weeks than at 24 weeks. A significant improvement was also observed in the original PANSS negative-symptom score (p=0.029). However, sulforaphane did not significantly improve the MATRICS Consensus Cognitive Battery composite score or its individual subscores, indicating no demonstrated benefit for cognitive impairment in this trial. The authors concluded that sulforaphane may have potential as an adjunctive intervention for negative symptoms in chronic schizophrenia, but its cognitive benefits remain unproven. Larger randomized controlled trials are needed to confirm its efficacy, establish the durability of symptom improvement and clarify its clinical role.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
This 24-week, double-blind, randomized trial evaluated adjunctive sulforaphane versus placebo in patients with chronic schizophrenia and significant negative symptoms, while existing antipsychotic regimens remained unchanged. A total of 42 patients were included in the statistical analysis: 28 received sulforaphane and 14 received placebo. Sulforaphane significantly reduced the negative-symptom score derived from the five-factor Positive and Negative Syndrome Scale (PANSS) model compared with placebo (p=0.007), with a significant time-by-treatment-group interaction (p=0.023). The between-group difference in negative symptoms was more pronounced at 12 weeks than at 24 weeks. A significant improvement was also observed in the original PANSS negative-symptom score (p=0.029). However, sulforaphane did not significantly improve the MATRICS Consensus Cognitive Battery composite score or its individual subscores, indicating no demonstrated benefit for cognitive impairment in this trial. The authors concluded that sulforaphane may have potential as an adjunctive intervention for negative symptoms in chronic schizophrenia, but its cognitive benefits remain unproven. Larger randomized controlled trials are needed to confirm its efficacy, establish the durability of symptom improvement and clarify its clinical role.
Today
Depemokimab offers twice-yearly dosing for severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps, significantly cutting exacerbations and hospital admissions.
2 days back
A novel copper metal-organic framework hydrogel remodels the uterine microenvironment to stimulate robust endometrial regeneration, reduce intrauterine fibrosis, and restore reproductive fertility, offering a groundbreaking strategy for managing refractory endometrial damage and Asherman syndrome.
2 days back
New research reveals that non-ablative radiotherapy suppresses ventricular tachycardia by increasing conduction velocity via NaV1.5 upregulation and action potential prolongation. However, sustained sodium current elevation and depressed calcium handling highlight the need for careful clinical translation.
5 days back
A single-cell transcriptomic atlas reveals how peripheral nerve injuries cause dorsal root ganglion remodeling. By evaluating proximal nerve crush and resection, researchers identify distinct glial and immune programs that resolve neuropathic pain and promote regeneration.
2 days back
A breakthrough study demonstrates that fullerol-primed extracellular vesicles generated in a 3D SECCS bioreactor attenuate ferroptosis and restore myogenic regeneration in diabetes via the FOXO3 pathway, offering a cell-free therapeutic strategy for diabetic musculoskeletal degeneration.
2 days back
